UNIPRINT.NET
12.4.2016 15:49:48 CEST | Business Wire | Press release
UniPrint.net Corp , industry leader in printing virtualization technology, today announces the release of 3 print appliances – UniPrint Infinity™ vPad Pro, vPad Touch, and vPad CE . The multi-purpose, printer-vendor independent appliances are designed to enable on demand printing with security, and low maintenance and high speed remote printing across offices and geo locations, while the UniPrint Infinity printing software is in use. UniPrint Infinity vPads can also replace remote site or branch Windows print servers, making the process of consolidation into the data center much simpler, and ongoing IT support costs of remote print servers a thing of the past.
With the advent of cloud technology, an increasing number of organizations are moving to consolidate their data centers, be it on-premises or off-premises, in an effort to reduce IT support costs, provide centralized administration, and secure data and printer access. Yet remote print servers have remained a burden to manage and a challenge to support, especially when combined with frequent changes and updates, causing remote print speed issues and security implications for businesses with dispersed locations.
These industry-first vPads feature dual security via 256 bit encryption, user-authenticated print release, and print stream compression which reduces print data sizes by up to 95%, promoting fast data transmission and printing at remote sites . They can also act as remote print server gateway devices, eliminating the need to procure and support Windows hardware and software in remote locations.
“These simple, plug and play devices are game changers. They help to unleash the true power of the UniPrint Infinity software, allowing enterprise users to print in an unprecedentedly secure and speedy way. The 3 models allow the customers to have the best choice and within budget,” noted UniPrint.net Chief Technical Officer Arron Fu.
The vPads can provide support to multiple printers and are compatible with any computing environment. Installation is a straightforward plug and play, and no configuration is required by any personnel in the remote site.
For further information on UniPrint Infinity and vPads, or to download a free product trial, please visit www.uniprint.net or email sales@uniprint.net . Alternatively, sign up for our free 30-minute webinar “Do you Really Need Remote Print Servers?” April 21, 2016 at 1:00 PM U.S. Eastern Standard Time.
About UniPrint.net
UniPrint.net is the recognized leader in printing virtualization. The newest solution in UniPrint’s patented, award-winning product line, UniPrint Infinity v9 is the industry’s first truly secure enterprise-wide solution for any computing environment. Enabling anywhere, anytime, any device secure pull printing, UniPrint Infinity comes with proven ROI through its statistics module, print document archiving functionality and secure mobile printing modules, and high availability with load balancing. UniPrint Infinity replaces all manufacturer printer drivers with a single PDF generator to promote faster, more efficient printing, helping organizations to improve both productivity and return on investments.
UniPrint and UniPrint Infinity are the trademarks of UniPrint.net. All other trademarks and registered trademarks are properties of their respective owners.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160412006028/en/
Contact:
UniPrint.net
Katherine Cheung, Marketing Manager, +1 416-503-9800
ext. 8566
katherine.cheung@uniprint.net
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom